Hayashi Hidetoshi 林秀敏

… Alternative Names

HAYASHI Hidetoshi 林秀敏

Less

Researcher Number	10548621
Other IDs
Affiliation (Current)	2025: 近畿大学, 医学部, 教授
Affiliation (based on the past Project Information) *help	2023 – 2024: 近畿大学, 医学部, 教授 2019 – 2022: 近畿大学, 医学部, 講師 2021: 近畿大学, 医学部, 特命准教授 2016 – 2017: 近畿大学, 医学部, 講師
Review Section/Research Field	Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related / Medical genome science Except Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related / Basic Section 50010:Tumor biology-related
Keywords	Principal Investigator 免疫チェックポイント阻害剤 / 免疫チェックポイント阻害薬 / 肺癌 / 抗PD-1抗体 / 遺伝子発現 / 臨床腫瘍 / 分子標的治療薬 / 免疫チェックポイント / 個別化医療 / バイオマーカー … More Except Principal Investigator … More リキッドバイオプシー / 循環腫瘍DNA / メチル化 / 機械学習 / 原発不明癌 / リスク因子 / 免疫関連有害事象 / 免疫チェックポイント阻害薬 Less

Validation study of a model for estimating the primary organ of cancer of unknown primary by methylation analysis of circulating tumor DNA
- Principal Investigator
  
  西尾和人
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Kindai University
Analysis of the risk factors for the development and severity of immune-related adverse events by immune checkpoint inhibitors
- Principal Investigator
  
  谷崎潤子
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Kindai University
Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.Principal Investigator
- Principal Investigator
  
  HAYASHI Hidetoshi
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Kindai University
Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarkerPrincipal Investigator
- Principal Investigator
  
  HAYASHI Hidetoshi
- Project Period (FY)
  2016 – 2017
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Medical genome science
- Research Institution
  Kindai University

All 2024 2023 2017

All Journal Article Presentation

[Journal Article] TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer2024
- Author(s)
  Arimura Akiko、Sakai Kazuko、Kaneshiro Kazuhisa、Morisaki Takafumi、Hayashi Saori、Mizoguchi Kimihisa、Yamada Mai、Kai Masaya、Ono Mayumi、Nishio Kazuto、Nakamura Masafumi、Kubo Makoto
- Journal Title
  
  Cancers
  
  Volume: 16 Issue: 6 Pages: 1184-1184
- DOI
  10.3390/cancers16061184
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-21K19532, KAKENHI-PROJECT-23K27468
[Journal Article] Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade2024
- Author(s)
  Hayashi Hidetoshi, Chamoto Kenji, Hatae Ryusuke, Kurosaki Takashi, Togashi Yosuke, Fukuoka Kazuya, Goto Megumi, Chiba Yasutaka, Tomida Shuta, Ota Takayo, Haratani Koji, Takahama Takayuki, Tanizaki Junko, Yoshida Takeshi, Iwasa Tsutomu, Tanaka Kaoru, Takeda Masayuki, Hirano Tomoko, Sakai Kazuko, Nishio Kazuto, etc
- Journal Title
  
  Journal of Clinical Investigation
  
  Volume: 134 Issue: 7
- DOI
  10.1172/jci168318
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-23K27468
[Journal Article] 肺癌におけるEGFR遺伝子変異と免疫チェックポイント阻害薬2017
- Author(s)
  林秀敏、光冨徹哉
- Journal Title
  
  癌と化学療法
  
  Volume: 未定
- Data Source
  KAKENHI-PROJECT-16K21506
[Journal Article] Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status After Disease Progression During EGFR-TKI Treatment2017
- Author(s)
  K. Haratani, H. Hayashi*, T. Tanaka, H. Kaneda, Y. Togashi, K. Sakai, K. Hayashi, S. Tomida, Y. Chiba, K. Yonesaka, Y. Nonagase, T. Takahama, J. Tanizaki, K. Tanaka, T. Yoshida, K. Tanimura, M. Takeda, H. Yoshioka, T. Ishida, T. Mitsudomi, K. Nishio and K. Nakagawa
- Journal Title
  
  Annals of Oncology
  
  Volume: in press Issue: 7 Pages: 1532-1539
- DOI
  10.1093/annonc/mdx183
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PROJECT-16K21506, KAKENHI-PROJECT-17K18388, KAKENHI-PUBLICLY-16H01574, KAKENHI-PLANNED-17H06404, KAKENHI-PROJECT-17J09900
[Presentation] 原発不明がん患者を対象としたニボルマブの有効性に関する第II相試験（NivoCUP）のフォローアップ解析2023
- Author(s)
  船越洋平、谷崎潤子、米盛勧、秋吉宏平、上田弘樹、滝口裕一、三浦裕司、畝川芳彦、小峰啓吾、沖川佳子、木寺康裕、福岡和也、伊藤彰彦、千葉康敬、坂井和子、南博信、西尾和人、中川和彦、林秀敏
- Organizer
  第20回日本臨床腫瘍学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-23K27468
[Presentation] 原発不明がんに対するニボルマブの安全性と有効性：拡大治験（NivoCUP2, WJOG14620M）の初回結果報告2023
- Author(s)
  谷崎潤子、米盛勧、滝口裕一、秋吉宏平、小峰啓吾、小野澤祐輔、佐藤真利子、平田賢郎、尾上琢磨、大熊遼太朗、堀田洋介、南博信、、本多和典、陶山浩一、伊藤彰彦、千葉康敬、西尾和人、中川和彦、林秀敏
- Organizer
  第20回日本臨床腫瘍学会学術集会
- Invited
- Data Source
  KAKENHI-PROJECT-23K27468
[Presentation] EGFR遺伝子変異陽性非小細胞肺癌におけるEGFR-TKI耐性後T790M変異有無によるニボルマブ治療効果と腫瘍微小免疫環境の後向き検討2017
- Author(s)
  原谷浩司、林秀敏、田中妙、金田裕靖、冨樫庸介、坂井和子、吉岡弘鎮、光冨徹哉、西尾和人、中川和彦
- Organizer
  第15回日本臨床腫瘍学会学術集会
- Data Source
  KAKENHI-PROJECT-16K21506

1. 坂井和子 (20580559)

# of Collaborated Projects: 2 results

# of Collaborated Products: 2 results
2. 冨田秀太 (10372111)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
3. 伊藤彰彦 (80273647)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. 高濱隆幸 (90716359)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. 原谷浩司 (90760447)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
6. 谷崎潤子 (90548637)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
7. 磯本晃佑 (20847173)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 鈴木慎一郎 (60823614)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. 金村宙昌 (90845827)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
10. 西尾和人 (10208134)

# of Collaborated Projects: 1 results

# of Collaborated Products: 3 results
11. デベラスコマルコ (20449838)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
12. KUBO Makoto

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
13. 森瞳美

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
14. 森崎隆

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
15. 甲斐昌也

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Hayashi Hidetoshi 林 秀敏

HAYASHI Hidetoshi 林 秀敏

Research Projects

Research Products

Co-Researchers

Validation study of a model for estimating the primary organ of cancer of unknown primary by methylation analysis of circulating tumor DNA

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Analysis of the risk factors for the development and severity of immune-related adverse events by immune checkpoint inhibitors

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarkerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade2024

Author(s)

Journal Title

DOI

Data Source

[Journal Article] 肺癌におけるEGFR遺伝子変異と免疫チェックポイント阻害薬2017

Author(s)

Journal Title

Data Source

[Journal Article] Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status After Disease Progression During EGFR-TKI Treatment2017

Author(s)

Journal Title

DOI

Data Source

[Presentation] 原発不明がん患者を対象としたニボルマブの有効性に関する第II相試験（NivoCUP）のフォローアップ解析2023

Author(s)

Organizer

Data Source

[Presentation] 原発不明がんに対するニボルマブの安全性と有効性：拡大治験（NivoCUP2, WJOG14620M）の初回結果報告2023

Author(s)

Organizer

Data Source

[Presentation] EGFR遺伝子変異陽性非小細胞肺癌におけるEGFR-TKI耐性後T790M変異有無によるニボルマブ治療効果と腫瘍微小免疫環境の後向き検討2017

Author(s)

Organizer

Data Source

Hayashi Hidetoshi 林秀敏

HAYASHI Hidetoshi 林秀敏